Study says docs favor COI disclosure

Share this article:
Lisa Iezzoni, one of the study's authors
Lisa Iezzoni, one of the study's authors

Most physicians agree that it's important to disclose to patients any financial relationships with drug and device companies.

About 65% of the 1,800 physicians surveyed in a 2009 study discussed in Health Affairs support disclosing potential conflicts of interest (COI) to patients. But 35.4% still do not completely agree that they should disclose.

Requiring disclosure of financial ties “could be perceived by physicians as something new and intrusive,” Lisa Iezzoni, a professor at Harvard Medical School and lead author of the study, told MM&M.

The Sunshine Act stipulates that drug and device companies start reporting payments of $10 or more to physicians by March 2013.  But disclosure to patients may not immediately follow. “Physicians who do not support public disclosure might resist communicating this information to inquiring patients,” the study authors note, “or might make these conversations more difficult.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?